Contracts › 75N91022F00001
75N91022F00001: Prevent Cancer Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers-- Targeting the Parp Pathway for the Prevention of Breast Cancer
Awarded to The Univeristy of Texas M.D. Anderson Cancer Center by National Institutes of Health (NIH).
$1.1Mobligated
$1.1Mpotential value
31 May 2027current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75N91022F00001 |
|---|---|
| Vehicle | 75N91019D00021 |
| Awardee | The Univeristy of Texas M.D. Anderson Cancer Center |
| Awarding agency | National Institutes of Health (NIH) |
| Awarding office | NIH NCI |
| NAICS | 541714 Research and Development in Biotechnology (Except Nanobiotechnology) |
| PSC | AN12 Health R&D Services; Health Care Services; Applied Research |
| Place of performance | TX |
| Offers received | 1 |
| Period of performance | 01 June 2022 to 31 May 2027 |
| Potential end | 31 May 2027 |
| Estimated recompete solicitation | ~Q4 2026 (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 04 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541714 contracts · All expiring contracts · USASpending record